A drug for weight loss may reshape treatment for addiction
A small but striking Danish trial has found that semaglutide — the weekly injection that reshaped conversations about obesity — may also quiet the compulsion to drink, reducing heavy drinking days by more than double the rate of placebo in adults with alcohol use disorder. Published in The Lancet, the findings arrive against a backdrop of profound unmet need: 400 million people worldwide live with alcohol dependence, yet only three medications have ever been approved to treat it. The trial is modest in size and short in duration, but it points toward something larger — the possibility that drugs designed to regulate hunger may, in fact, be regulating something deeper in the human relationship with craving itself.
- Alcohol use disorder kills 2.6 million people annually and afflicts 400 million more, yet the medical world has produced only three approved treatments in decades of trying.
- In a 108-person trial, semaglutide slashed heavy drinking days from 17 to just 5 per month — a reduction twice as steep as placebo — and cut total alcohol consumption by 70 percent.
- The drug appears to work by dampening the brain's reward circuitry, suggesting that the same mechanism suppressing appetite may also suppress the pull of addiction.
- Researchers caution that the sample is small and no long-term follow-up was conducted, leaving open the critical question of whether the benefits endure once treatment stops.
- In India, semaglutide's patent expired in March 2026, potentially opening the door to affordable generic versions at precisely the moment clinical evidence for addiction treatment is building.
A Danish clinical trial has found that semaglutide — the weekly injection celebrated for weight loss — can dramatically reduce heavy drinking in people with alcohol use disorder. Published in The Lancet, the results suggest that GLP-1 drugs, which mimic gut hormones to suppress appetite, may have therapeutic reach far beyond obesity and diabetes.
The trial enrolled 108 adults with obesity seeking treatment for alcohol dependence. All received cognitive behavioral therapy alongside either semaglutide or a placebo. Participants began with an average of 17 heavy drinking days per month. After six months, the semaglutide group had fallen to roughly five days — a drop of 12 — while the placebo group declined more modestly to nine. Total alcohol consumption among semaglutide users fell by approximately 70 percent, compared to roughly 47 percent in the placebo group.
The findings matter because the scale of the problem is immense and the toolkit for addressing it is thin. The WHO estimates 400 million people worldwide live with alcohol use disorder, which caused 2.6 million deaths in 2019 alone. Despite decades of research, the FDA has approved only three medications for alcohol dependence. GLP-1 drugs appear to work partly by dampening the brain's reward pathways — the same circuitry that drives craving — which may explain their effect on drinking behavior.
The study's authors acknowledged its limitations: the sample size is small, and there was no follow-up after the trial ended to determine whether gains persisted. Still, they described the results as showing 'robust therapeutic effects' and called GLP-1s a potential novel treatment target for the condition.
In India, where semaglutide arrived under brand names like Wegovy and Ozempic before its patent expired in March 2026, the convergence of new clinical evidence and the prospect of generic access raises the possibility that these drugs could soon be studied and prescribed for addiction at a scale previously unimaginable — if larger, longer trials confirm what this early data suggests.
A Danish clinical trial has found that semaglutide, the same weekly injection that became famous for weight loss, can substantially reduce heavy drinking in people struggling with alcohol use disorder. The results, published in The Lancet, suggest that GLP-1 drugs—a class of medications that mimic gut hormones to suppress appetite—may have therapeutic reach far beyond obesity and diabetes.
The trial enrolled 108 adults with obesity who were seeking treatment for alcohol dependence. All participants received cognitive behavioral therapy alongside either a weekly 2.4-milligram dose of semaglutide or a placebo. At the study's start, patients reported an average of 17 heavy drinking days in the previous month. After six months, those on semaglutide had reduced that to roughly five days—a drop of 12 days. The placebo group saw a more modest decline to nine days, a reduction of eight days. In terms of total alcohol consumption, semaglutide users cut their intake by roughly 70 percent, from an average of 2,200 grams per month to 650 grams, while the placebo group dropped from 2,200 grams to 1,175 grams.
The findings arrive at a moment when alcohol use disorder remains a staggering global health burden. The World Health Organization estimates that roughly 400 million people worldwide—about 7 percent of the population aged 15 and older—live with alcohol use disorder. In 2019 alone, alcohol consumption caused 2.6 million deaths globally, spanning noncommunicable diseases like liver cirrhosis and cancer, injuries from accidents and violence, and communicable diseases. Despite decades of research, the U.S. Food and Drug Administration has approved only three medications to treat alcohol dependence: disulfiram, acamprosate, and naltrexone. The scarcity of effective options underscores why this trial matters.
Semaglutide and related GLP-1 drugs work by triggering brain pathways involved in appetite regulation and reward processing. That mechanism—dampening the drive to consume something the body craves—appears to extend to alcohol. The authors of the Lancet study wrote that semaglutide "showed robust therapeutic effects" and that the trial "supports previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment target for alcohol use disorder."
The study does carry significant limitations. The sample size of 108 is small, and researchers did not follow participants after the trial ended to determine whether the benefits persisted or whether heavy drinking resumed. The authors themselves flagged these gaps. Yet they argue the findings add to mounting evidence that GLP-1s could reshape treatment for a condition affecting hundreds of millions of people globally.
In India, semaglutide arrived under brand names like Wegovy and Ozempic, while tirzepatide—another GLP-1 drug—launched as Mounjaro. These medications became widely popular within months of their introduction. In March 2026, semaglutide's patent expired in India, opening the door to generic versions. The convergence of patent expiration, growing clinical evidence, and the sheer scale of alcohol use disorder suggests that GLP-1 drugs could soon be studied and prescribed for addiction treatment at a scale previously unimaginable. What remains to be seen is whether the promise of this single trial will hold up in larger, longer studies—and whether access to these medications will reach the populations most burdened by alcohol's toll.
Notable Quotes
Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment target for alcohol use disorder.— Authors of the Lancet study
The Hearth Conversation Another angle on the story
Why does a weight-loss drug suddenly matter for alcohol use disorder? That seems like a leap.
It's not as random as it sounds. These drugs work on reward pathways in the brain—the same circuits that drive cravings, whether for food or alcohol. When you dampen that signal, you reduce the compulsion to consume.
So the mechanism is the same?
Similar enough. Both obesity and alcohol dependence involve dysregulation of appetite and reward. The drug addresses that underlying biology rather than just the behavior.
The trial is only 108 people. Why should anyone take this seriously?
Because it's the first randomized trial of its kind, and the effect size is substantial—a 12-day reduction versus 8 days for placebo. It's small, yes, but it's a signal. And it comes at a moment when we have almost no new treatments for alcohol dependence.
What happens after the trial ends? Do people stay sober?
That's the honest answer: we don't know yet. There was no follow-up. That's the biggest gap. You need to know if the benefit lasts, if people relapse when they stop the drug, whether it works outside a controlled setting.
If this works, what changes?
Everything. Alcohol use disorder kills 2.6 million people a year globally. If GLP-1s become a standard treatment, you're potentially affecting hundreds of millions of people. And in India, where the drug just went generic, cost becomes less of a barrier.